ADS Diagnostic Limited disclosed its unaudited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27) through a regulatory filing to the Bombay Stock Exchange. The disclosure was made pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Board Meeting Details
The Board of Directors meeting was held on Thursday, August 13th, 2026. The meeting commenced at 12:05 p.m. and concluded at 13:10 p.m. The board reviewed and approved the unaudited standalone financial results for Q1 FY27.
Financial Performance (Q1 FY27 vs Q1 FY26 vs Q4 FY26)
Revenue and Income:
- Revenue from Operations (Net): ₹328.21 lakh (vs ₹426.68 lakh in Q1 FY26, vs ₹400.30 lakh in Q4 FY26)
- Other Operating Income: ₹23.33 lakh (vs ₹13.36 lakh in Q1 FY26, vs ₹3.68 lakh in Q4 FY26)
- Total Income: ₹351.54 lakh (vs ₹440.04 lakh in Q1 FY26, vs ₹403.98 lakh in Q4 FY26)
Expenses:
- Cost of Materials Consumed: ₹47.19 lakh (vs ₹222.18 lakh in Q1 FY26, vs ₹191.45 lakh in Q4 FY26)
- Employee Benefits Expense: ₹74.38 lakh (vs ₹68.38 lakh in Q1 FY26, vs ₹84.52 lakh in Q4 FY26)
- Depreciation and Amortization: ₹1.29 lakh (vs ₹2.84 lakh in Q1 FY26, vs ₹(1.75) lakh in Q4 FY26)
- Finance Costs: ₹10.27 lakh (vs ₹11.91 lakh in Q1 FY26, vs ₹13.45 lakh in Q4 FY26)
- Other Expenses: ₹214.38 lakh (vs ₹114.69 lakh in Q1 FY26, vs ₹99.23 lakh in Q4 FY26)
- Total Expenses: ₹347.51 lakh (vs ₹420.00 lakh in Q1 FY26, vs ₹386.90 lakh in Q4 FY26)
Profitability:
- Profit Before Tax and Exceptional Items: ₹4.03 lakh (vs ₹20.04 lakh in Q1 FY26, vs ₹17.08 lakh in Q4 FY26)
- Exceptional Items: None
- Profit Before Tax: ₹4.03 lakh (vs ₹20.04 lakh in Q1 FY26, vs ₹17.08 lakh in Q4 FY26)
- Tax Expense: ₹0.81 lakh (Current Income Tax) (vs ₹5.27 lakh in Q1 FY26, vs ₹5.45 lakh in Q4 FY26)
- Net Profit After Tax: ₹3.22 lakh (vs ₹14.77 lakh in Q1 FY26, vs ₹11.64 lakh in Q4 FY26)
- Other Comprehensive Income: None
- Total Comprehensive Income: ₹3.22 lakh (vs ₹14.77 lakh in Q1 FY26, vs ₹11.86 lakh in Q4 FY26)
Earnings Per Share (EPS):
- Basic EPS: ₹0.15 (vs ₹0.67 in Q1 FY26, vs ₹0.53 in Q4 FY26)
- Diluted EPS: ₹0.15 (vs ₹0.67 in Q1 FY26, vs ₹0.53 in Q4 FY26)
Capital Structure
- Paid-up Equity Share Capital: ₹219.28 lakh (unchanged from previous periods)
- Reserves (excluding Revaluation): ₹519.76 lakh (vs ₹434.43 lakh in previous periods)
Business Segment Information
The company is engaged in a single reportable segment: "Trading of diagnostic medical consumables & electronic consumables, servicing of medical equipments & machines" as per Ind AS 108.
Regulatory Compliance and Approval
The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors on August 13, 2026. The results have been prepared in compliance with Indian Accounting Standards (Ind AS) and SEBI Listing Regulations. The results are also available on the company's website at http://www.adsdiagnosticltd.com.
Auditor's Review
V. N. Purohit & Co., Chartered Accountants (Firm Regn. 304040E), issued an independent review report stating that based on their review, nothing has come to their attention that causes them to believe that the statement contains any material misstatement. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 issued by ICAI. The report was signed by Partner Om Prakash Pareek (Membership No. 014238) on August 13, 2026.